跳至主要内容
临床试验/NCT01825148
NCT01825148已完成不适用

Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4

Radboud University Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
pancreatic uptake of radiolabeled Exendin

研究概览

简要总结

The purpose of the study is to determine whether there are differences in pancreatic uptake of the radiotracer between healthy individuals and patients with type 1 diabetes. If T1D patients have a markedly reduced uptake, the compound may be suitable for estimation of pancreatic beta cell mass, i.e. the cells in the pancreas that produce insulin.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
21 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • type 1 Diabetes

排除标准

  • breast feeding

结局指标

主要结局

pancreatic uptake of radiolabeled Exendin

时间窗: 7 days

uptake will be given as counts per MBq injected activity as determined by calibrated SPECT/CT scanner with attenuation correction.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Martin Gotthardt

Prof. Dr.

Radboud University Medical Center

研究点 (1)

Loading locations...

相似试验

GLP-1 Receptor Targeting in Diabetic and Healthy... | 临床试验